Retinal Function and Morphology in Rabbit After Intravitreal Injection of VEGF Inhibitors

REFERENCES

• Wong TY, Wong T, Chakravarthy U et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology. 2008;115:116–126.
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth UM, Richard G, Augustin A et al.; European Society for Retina Specialists’ Guidelines Committee (EURETINA). Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand. 2007;85:486–494.
   PubMedGoogle Scholar
• Simó R, Hernández C. Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia. 2008;51:1574–1580.
   PubMed Web of Science ®Google Scholar
• Kriechbaum K, Michels S, Prager F et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol. 2008;92:518–522.
   PubMed Web of Science ®Google Scholar
• Kreutzer TC, Alge CS, Wolf AH et al. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol. 2008;92:351–355.
   PubMed Web of Science ®Google Scholar
• Michelson IC. The mode of development of the vascular system of the retina, with some observations on its significance for central retinal diseases. Eye. 1948:136–180.
   Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–1186.
   PubMed Web of Science ®Google Scholar
• Marneros AG, Fan J, Yokoyama Y et al. Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol. 2005;167:1451–1459.
   PubMed Web of Science ®Google Scholar
• Pieramici DJ, Rabena MD. Anti-VEGF therapy: comparison of current and future agents. Eye (Lond). 2008;22:1330–1336.
   PubMed Web of Science ®Google Scholar
• Klettner A, Roider J. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci. 2008;49:4523–4527.
   PubMed Web of Science ®Google Scholar
• Moreira IS, Fernandes PA, Ramos MJ. Vascular endothelial growth factor (VEGF) inhibition – a critical review. Anticancer Agents Med Chem. 2007;7:223–245.
   PubMed Web of Science ®Google Scholar
• Spitzer MS, Yoeruek E, Sierra A et al. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefes Arch Clin Exp Ophthalmol. 2007;245:1837–1842.
   PubMed Web of Science ®Google Scholar
• Ip MS, Scott IU, Brown GC et al.; American Academy of Ophthalmology. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology. 2008;115:1837–1846.
   PubMed Web of Science ®Google Scholar
• Patel PJ, Bunce C, Tufail A; ABC Trial Investigators. A randomised, double-masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age-related macular degeneration: clinical trial design. Trials. 2008;9:56.
   PubMed Web of Science ®Google Scholar
• Ziemssen F, Lüke M, Messias A et al.; Tuebingen Bevacizumab Study Group. Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients. Int Ophthalmol. 2008;28:101–109.
   PubMedGoogle Scholar
• Peters S, Heiduschka P, Julien S et al. Tübingen Bevacizumab Study Group. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol. 2007;143:995–1002.
   PubMed Web of Science ®Google Scholar
• Heiduschka P, Fietz H, Hofmeister S et al.; Tübingen Bevacizumab Study Group. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci. 2007;48:2814–2823.
   PubMed Web of Science ®Google Scholar
• Iriyama A, Chen YN, Tamaki Y, Yanagi Y. Effect of anti-VEGF antibody on retinal ganglion cells in rats. Br J Ophthalmol. 2007;91:1230–1233.
   PubMed Web of Science ®Google Scholar
• Saint-Geniez M, Maharaj AS, Walshe TE et al. Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors. PLoS ONE. 2008;3:e3554.
   PubMed Web of Science ®Google Scholar
• Stahl A, Feltgen N, Fuchs A, Bach M. Electrophysiological evaluation of retinal photoreceptor function after repeated bevacizumab injections. Doc Ophthalmol. 2009;118:81–88.
   PubMed Web of Science ®Google Scholar
• Maier M, Feucht N, Lanzi I, Kook. P, Lohmann CP. Retinochoroidopathy after intravitreal anti-VEGF treatment. Ophthalmologe. 2008. doi:10.1007/s00347-008-1839-3
   Web of Science ®Google Scholar
• Lipski A, Bornfeld N, Jurklies B. Multifocal electroretinography in patients with exudative amd and intravitreal treatment with pegaptanib sodium. Retina (Philadelphia, Pa). 2007;27:864–872.
   PubMed Web of Science ®Google Scholar
• Pedersen KB, Møller F, Sjølie AK, Andréasson S. Electrophysiological assessment of retinal function during 6 months of bevacizumab treatment in neovascular age-related macular degeneration. Retina (Philadelphia, Pa). 2010;30:1025–1033.
   PubMed Web of Science ®Google Scholar
• Wu WC, Yeh PT, Chen SN, Yang CM, Lai CC, Kuo HK. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan. Ophthalmology. 2011;118:176–183.
   PubMed Web of Science ®Google Scholar
• Kusaka S, Shima C, Wada K et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol. 2008;92:1450–1455.
   PubMed Web of Science ®Google Scholar
• Tasman W, Jaeger EA (Eds.). Duane’s foundations of clinical ophthalmology. Vol 1., Chap 16. Philadelphia, PA: Lippincott Williams & Wilkins, 1998.
   Google Scholar
• Larsen JS. The sagittal growth of the eye. 3. Ultrasonic measurement of the posterior segment (axial length of the vitreous) from birth to puberty. Acta Ophthalmol (Copenh). 1971;49:441–453.
   PubMed Web of Science ®Google Scholar
• Prince JH: The vitreous. In: Prince JH (Ed.) The Rabbit in Eye Research. Springfield, Charles C Thomas, 1964; pp. 372–384.
   Google Scholar
• Gjörloff K, Andréasson S, Ehinger B. Standardized full-field electroretinography in rabbits. Doc Ophthalmol. 2004;109:163–168.
   PubMed Web of Science ®Google Scholar
• Marmor MF, Fulton AB, Holder GE, Miyake Y, Brigell M, Bach M; International Society for Clinical Electrophysiology of Vision. ISCEV Standard for full-field clinical electroretinography (2008 update). Doc Ophthalmol. 2009;118:69–77.
   PubMed Web of Science ®Google Scholar
• Gjörloff KW, Andréasson S, Ghosh F. mfERG in normal and lesioned rabbit retina. Graefes Arch Clin Exp Ophthalmol. 2006;244:83–89.
   PubMed Web of Science ®Google Scholar
• Heilweil G, Komarowska I, Zemel E, Loewenstein A, Perlman I. Normal physiological and pathophysiological effects of trypan blue on the retinas of albino rabbits. Invest Ophthalmol Vis Sci. 2010;51:4187–4194.
   PubMed Web of Science ®Google Scholar
• Shahar J, Avery RL, Heilweil G et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina (Philadelphia, Pa). 2006;26:262–269.
   PubMed Web of Science ®Google Scholar
• Koistinaho J, Sagar SM. Localization of protein kinase C subspecies in the rabbit retina. Neurosci Lett. 1994;177:15–18.
   PubMed Web of Science ®Google Scholar
• Wood JP, McCord RJ, Osborne NN. Retinal protein kinase C. Neurochem Int. 1997;30:119–136.
   PubMed Web of Science ®Google Scholar
• Blanks JC, Johnson LV. Specific binding of peanut lectin to a class of retinal photoreceptor cells. A species comparison. Invest Ophthalmol Vis Sci. 1984;25:546–557.
   PubMed Web of Science ®Google Scholar
• Casini G, Rickman DW, Brecha NC. AII amacrine cell population in the rabbit retina: identification by parvalbumin immunoreactivity. J Comp Neurol. 1995;356:132–142.
   PubMed Web of Science ®Google Scholar
• MacKenzie D, Arendt A, Hargrave P, McDowell JH, Molday RS. Localization of binding sites for carboxyl terminal specific anti-rhodopsin monoclonal antibodies using synthetic peptides. Biochemistry. 1984;23:6544–6549.
   PubMed Web of Science ®Google Scholar
• Massey SC, Mills SL. A calbindin-immunoreactive cone bipolar cell type in the rabbit retina. J Comp Neurol. 1996;366:15–33.
   PubMed Web of Science ®Google Scholar
• Wu WC, Lai CC, Chen KJ et al. Long-term tolerability and serum concentration of bevacizumab (avastin) when injected in newborn rabbit eyes. Invest Ophthalmol Vis Sci. 2010;51:3701–3708.
   PubMed Web of Science ®Google Scholar
• Arraes JC, Tedesco RC, Arraes TA, Silva EB, Ventura A, Avila MP. Intravitreal bevacizumab in pigmented rabbit eyes: histological analysis 90 days after injection. Arq Bras Oftalmol. 2009;72:656–660.
   PubMed Web of Science ®Google Scholar
• Klettner AK, Kruse ML, Meyer T, Wesch D, Kabelitz D, Roider J. Different properties of VEGF-antagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells. Graefes Arch Clin Exp Ophthalmol. 2009;247:1601–1608.
   PubMed Web of Science ®Google Scholar
• Hood DC, Birch DG. Beta wave of the scotopic (rod) electroretinogram as a measure of the activity of human on-bipolar cells. J Opt Soc Am A Opt Image Sci Vis. 1996;13:623–633.
   PubMed Web of Science ®Google Scholar
• Xia P, Aiello LP, Ishii H et al. Characterization of vascular endothelial growth factor’s effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest. 1996;98:2018–2026.
   PubMed Web of Science ®Google Scholar